

# Andrew D Chantry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3735155/publications.pdf>

Version: 2024-02-01

39  
papers

1,173  
citations

567281

15  
h-index

377865

34  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 425-436.	2.8	230
2	Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- $\kappa$ B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2006, 135, 688-692.	2.5	217
3	Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2633-2646.	2.8	129
4	Guidelines for the use of imaging in the management of patients with myeloma. <i>British Journal of Haematology</i> , 2017, 178, 380-393.	2.5	101
5	Myeloma bone disease: pathogenesis, current treatments and future targets. <i>British Medical Bulletin</i> , 2014, 111, 117-138.	6.9	61
6	New agents in the Treatment of Myeloma Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 196-209.	3.1	37
7	NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. <i>PLoS ONE</i> , 2015, 10, e0119546.	2.5	36
8	A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice. <i>Stem Cells</i> , 2012, 30, 1134-1143.	3.2	31
9	ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. <i>Stem Cell Research and Therapy</i> , 2020, 11, 516.	5.5	25
10	Long-Term Outcomes of Myeloablation and Autologous Transplantation of Relapsed Acute Myeloid Leukemia in Second Remission: A British Society of Blood and Marrow Transplantation Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1310-1317.	2.0	22
11	Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 783-796.	2.8	22
12	Apomine $\alpha$ , $\zeta$ , an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. <i>International Journal of Cancer</i> , 2007, 120, 1657-1663.	5.1	20
13	The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2- $\beta$ ]Pyridin-3-yl)-Ethyl-Bisphosphonate). <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1860-1869.	2.8	19
14	Time to redefine Myeloma. <i>British Journal of Haematology</i> , 2015, 171, 1-10.	2.5	18
15	The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. <i>Oncogene</i> , 2020, 39, 5001-5014.	5.9	17
16	Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. <i>British Medical Bulletin</i> , 2015, 113, 15-30.	6.9	16
17	Mechanisms and treatment of bone pain in multiple myeloma. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 408-416.	1.3	16
18	Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. <i>Journal of Bone Oncology</i> , 2019, 17, 100243.	2.4	15

#	ARTICLE	IF	CITATIONS
19	Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international interlaboratory study: Is it ready for primetime use?. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 201-208.	1.5	15
20	TGF $\beta$ 2 Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2311-2326.	2.8	14
21	Mesenchymal lineage cells and their importance in B lymphocyte niches. <i>Bone</i> , 2019, 119, 42-56.	2.9	13
22	Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo. <i>PLoS ONE</i> , 2012, 7, e35830.	2.5	13
23	Multiple myeloma—A painful disease of the bone marrow. <i>Seminars in Cell and Developmental Biology</i> , 2021, 112, 49-58.	5.0	10
24	Assessment of droplet digital polymerase chain reaction for measuring <i>BCR-ABL1</i> in chronic myeloid leukaemia in an international interlaboratory study. <i>British Journal of Haematology</i> , 2021, 194, 53-60.	2.5	10
25	Spontaneous splenic rupture: an unusual presentation of CML. <i>BMJ Case Reports</i> , 2011, 2011, bcr0220113879-bcr0220113879.	0.5	9
26	Low-dose methotrexate in myeloproliferative neoplasm models. <i>Haematologica</i> , 2017, 102, e336-e339.	3.5	9
27	ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. <i>PLoS ONE</i> , 2018, 13, e0199517.	2.5	9
28	Comparison of the CELLEX $\phi$ and UVAR $\phi$ XTS $\phi$ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease. <i>Journal of Clinical Apheresis</i> , 2017, 32, 462-473.	1.3	7
29	Myeloma Bone Disease: The Osteoblast in the Spotlight. <i>Journal of Clinical Medicine</i> , 2021, 10, 3973.	2.4	7
30	A university-led initiative to promote voluntary non-remunerated blood donation in a developing country. <i>Transfusion and Apheresis Science</i> , 2019, 58, 674-679.	1.0	6
31	The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 5687.	3.7	6
32	Bone Pain in Multiple Myeloma (BPMM)—A Protocol for a Prospective, Longitudinal, Observational Study. <i>Cancers</i> , 2021, 13, 1596.	3.7	5
33	What Can Patient Narratives Reveal to Us About the Experience of a Diagnosis of Myeloma? A Qualitative Scoping Review. <i>Journal of Patient Experience</i> , 2022, 9, 237437352210791.	0.9	3
34	Researching surviving cancer and sexuality using visual methods: a reflection on research rationale and negotiating ethical issues. <i>Families, Relationships and Societies</i> , 2015, 4, 483-492.	0.9	2
35	Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018. <i>Blood</i> , 2018, 132, 4743-4743.	1.4	1
36	Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006, 108, 506-506.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo. Blood, 2021, 138, 1594-1594.	1.4	1
38	Myeloma bone disease “ pathogenesis of bone destruction and therapeutic strategies. , 0, , 96-109.		0
39	Pre-clinical investigation of inhibition of the DNA damage response as a targeted therapy in myeloproliferative neoplasms shows synergism of ATR inhibitors with standard-of-care treatment.. , 2021, 3, .		0